Short answer: With 2 mL of bacteriostatic water in a CJC-1295 + Ipamorelin, 5 mg + 5 mg vial (5 mg CJC-1295 (no DAC) + 5 mg Ipamorelin), every 10 units on a U-100 insulin syringe holds 250 mcg CJC-1295 (no DAC) and 250 mcg Ipamorelin. The ratio is fixed, so you cannot change one peptide without changing the others. Amounts are arithmetic on the label, not dose advice.
This blend puts CJC-1295 without DAC (also called Mod GRF 1-29) and ipamorelin in one vial. Blends are almost always the no-DAC version; CJC-1295 with DAC is a different, long-acting molecule. Check your label.
Most listings are 5 mg + 5 mg (10 mg total). A 2 mg + 2 mg vial also appears. Both are 1:1, so each draw holds equal amounts of the two.
| Peptide | Commonly labeled | Share of vial | Guide |
|---|---|---|---|
| CJC-1295 (no DAC) | 5 mg | 50% | CJC-1295 (no DAC) guide |
| Ipamorelin | 5 mg | 50% | Ipamorelin guide |
| Peptide | Commonly labeled | Share of vial | Guide |
|---|---|---|---|
| CJC-1295 (no DAC) | 2 mg | 50% | CJC-1295 (no DAC) guide |
| Ipamorelin | 2 mg | 50% | Ipamorelin guide |
The water volume changes how big each draw is, not what is in the vial. The highlighted row is 2 mL.
| Water added | Units in vial | CJC-1295 (no DAC) / 10 units | Ipamorelin / 10 units |
|---|---|---|---|
| 2 mL | 200 | 250 mcg | 250 mcg |
| 3 mL | 300 | 166.7 mcg | 166.7 mcg |
| 5 mL | 500 | 100 mcg | 100 mcg |
| Water added | Units in vial | CJC-1295 (no DAC) / 10 units | Ipamorelin / 10 units |
|---|---|---|---|
| 2 mL | 200 | 100 mcg | 100 mcg |
| 3 mL | 300 | 66.7 mcg | 66.7 mcg |
| 5 mL | 500 | 40 mcg | 40 mcg |
| Units drawn | Volume | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|---|
| 5 units | 0.05 mL | 125 mcg | 125 mcg |
| 10 units | 0.1 mL | 250 mcg | 250 mcg |
| 20 units | 0.2 mL | 500 mcg | 500 mcg |
| 30 units | 0.3 mL | 750 mcg | 750 mcg |
For any other vial, water volume or draw, the free peptide blend calculator does the same math for 2 to 5 peptides.
mg of that peptide ÷ mL of water. For CJC-1295 + Ipamorelin, 5 mg + 5 mg with 2 mL: CJC-1295 (no DAC) 5 ÷ 2 = 2.5 mg/mL, Ipamorelin 5 ÷ 2 = 2.5 mg/mL.amount ÷ its concentration = mL. Example: 250 mcg of Ipamorelin is 0.25 ÷ 2.5 = 0.1 mL.mL × 100 on a U-100 syringe: 0.1 × 100 = 10 units.mL × concentration for each other peptide: 250 mcg CJC-1295 (no DAC).A blend is one solution, so every draw takes the same share of each peptide. In the example above, drawing 10 units for 250 mcg of Ipamorelin also gives 250 mcg CJC-1295 (no DAC). Doubling the draw to 20 units doubles all of them, to 500 mcg CJC-1295 (no DAC). There is no draw that changes one peptide and leaves the others where they are.
More or less water does not help either: it changes how many units each draw is, not the ratio between the peptides. If you need to set the amount of each peptide on its own, they have to be in separate vials (a stack), each with its own single-peptide calculation.
We found no published human study of CJC-1295 + Ipamorelin blend as a blend. Below is what is published for each peptide on its own. "Amounts studied" are what a study gave or reported, often by a different route; they are not personalized advice. Confirm anything about your own use with your prescriber.
Not FDA approved. We found no published human trials of CJC-1295 without DAC (Mod GRF 1-29). The published human study usually quoted for "CJC-1295" used the DAC version, a different, long-acting molecule with an estimated half-life of 5.8 to 8.1 days. [1]
Amounts studied: None published for the no-DAC version. The DAC version was given under the skin in healthy adults; those amounts do not carry over to the no-DAC peptide in this blend.
Not FDA approved. It has been studied in people: a pharmacokinetic study in healthy men measured a half-life of about 2 hours, and a phase 2 trial after bowel surgery found no significant difference from placebo on its main outcome. [2][3][4]
Amounts studied: Both human studies gave it into a vein: infusions of 4.21 to 140.45 nmol/kg over 15 minutes (healthy men), and 0.03 mg/kg twice daily for up to 7 days (after bowel surgery). No published trial gave it under the skin or in a blend.
Regulatory status. As of October 2026 none of the peptides in these blends is FDA approved. In July 2026 an FDA advisory committee voted 8 to 6 to recommend adding BPC-157, KPV and TB-500 to the list of substances pharmacies may compound. FDA staff had recommended against it, the vote is not binding, and none has been added yet. [5]
Blend compositions were checked against several retail product listings in October 2026. We do not name or link sellers.